COMMUNIQUÉS West-GlobeNewswire
-
Rentschler Biopharma appoints Dr. Veit Bergendahl as Chief Operating Officer and member of the executive board
11/02/2026 -
PL BioScience Wins Regulatory Certification from Japan’s PMDA
11/02/2026 -
AscellaHealth Expands International Operations, Broadens Executive Leadership to Accelerate Global Market Access for Life Sciences
11/02/2026 -
NTG Nordic Transport Group A/S - 2025 Annual Report Conference Call
11/02/2026 -
Madrigal Expands its MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical siRNA Programs
11/02/2026 -
Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress
11/02/2026 -
HepaRegeniX Completes Phase Ib Study of HRX-215 to Enhance Liver Regeneration in Patients Undergoing Minor Liver Resection
11/02/2026 -
SEISMIC consortium secures EUR 23.5 million IHI grant to pioneer next-generation minimally invasive brain treatments
11/02/2026 -
Bioxytran Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance with ProLectin-MBioxytran
11/02/2026 -
Secura Bio Expands Chief Financial Officer Will Brown’s Leadership Role to Include Chief Operating Officer
11/02/2026 -
InfiniHealth Medical Group Announces Integrated Multispecialty Care Model to Support Coordinated Specialty Services Across New Jersey
11/02/2026 -
Zelluna selects Medpace as CRO for ZIMA-101 first-in-human clinical trial
11/02/2026 -
Reset Health Further Strengthens Advisory Board With Appointment of Pinder Sahota
11/02/2026 -
Nasus Pharma Announces Pricing of $15.0 Million Private Placement
11/02/2026 -
Galecto Announces Pricing of $275 Million Underwritten Public Offering
11/02/2026 -
Berlin Protocol Performance Enhancer Product Information Updated — What Do Consumers Consider When Researching Male Enhancement Supplement Options in 2026?
11/02/2026 -
Neuronetics Announces Selected Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results
10/02/2026 -
DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting
10/02/2026 -
Avicanna Announces Closing of Non-Brokered Private Placement
10/02/2026
Pages